Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis

被引：9
|
作者：
Nie, Run-Cong [1 ]
Duan, Shu-Qiang YuanJin-Ling [1 ,3 ]
Liang, Yao [1 ]
Chen, Xiao-Jiang [1 ]
Chen, Yong-Ming [1 ]
Luo, Tian-Qi [1 ]
Chen, Guo-Ming [1 ]
Wang, Yun [2 ]
Li, Yuan-Fang [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Dept Gastr Surg,Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Hematol Oncol,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou 510060, Peoples R China
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 18期
关键词：
efficacy; immunotherapy; overall survival; PD-1; PD-L1; smoking; OPEN-LABEL; CANCER-IMMUNOTHERAPY; CHOICE CHEMOTHERAPY; SOLID TUMORS; NIVOLUMAB; PEMBROLIZUMAB; DOCETAXEL; BLOCKADE; ATEZOLIZUMAB; MULTICENTER;
D O I：
10.2217/imt-2020-0007
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Aim:This study aimed to evaluate the relationship between smoking status and efficacy of PD-1/PD-L1 inhibitors compared with conventional agents.Materials & methods:We reviewed Phase II/III trials of PD-1/PD-L1 inhibitors that reported hazard ratio (HR) in current/former and never smoking patients.Results: 15 qualifying trials comprising 9073 patients were eligible in this study. Compared with conventional agents, PD-1/PD-L1 inhibitors correlated with prolonged progression-free survival (HR: 0.73; 0.58-0.92) and overall survival (HR: 0.75; 0.71-0.80) in current/former smoker patients but not in never-smoker patients (HR: 1.15 and 0.86 for progression-free survival and overall survival, respectively; both p > 0.05) irrespective of cancer type, target of experimental agents and treatment strategy.Conclusion:There exit smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy.
引用
收藏
页码：1313 / 1324
页数：12
相关论文
共 50 条
  • [1] The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
    Chen, Ke
    Wang, Xiao
    Yang, Liu
    Chen, Zheling
    CANCER CONTROL, 2021, 28
  • [2] Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
    Ma, Long
    Jin, Gang
    Yao, Keying
    Yang, Yi
    Chang, Ruitong
    Wang, Wenhao
    Liu, Jiawei
    Zhu, Zijiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiao-Jiang
    Yuan, Shu-Qiang
    Duan, Jin-Ling
    Chen, Yong-Ming
    Chen, Shi
    Wang, Yun
    Li, Yuan-Fang
    DISEASE MARKERS, 2020, 2020
  • [4] Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis
    Liu, Haoran
    Ye, Tao
    Yang, Xiaoqi
    Lv, Peng
    Wu, Xiaoliang
    Thou, Hui
    Lu, Hongyan
    Tang, Kun
    Ye, Zhangqun
    DISEASE MARKERS, 2020, 2020
  • [5] PREDICTIVE AND PROGNOSTIC ROLE OF PD-L1 IN UROTHELIAL CARCINOMA PATIENTS WITH ANTI-PD-1/PD-L1 THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Tang, Kun
    Jiang, Kehua
    Zhou, Hui
    Liu, Haoran
    Ye, Zhangqun
    Xu, Hua
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1040 - E1040
  • [6] Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis
    Habibi, Mohammad Amin
    Mirjani, Mohammad Sina
    Ahmadvand, Muhammad Hussain
    Delbari, Pouria
    Eftekhar, Mohammad Shahir
    Ghazizadeh, Yalda
    Ghezel, Mohammad Amin
    Rad, Romina Hamidi
    Vakili, Kimia Ghazi
    Lotfi, Sohrab
    Minaee, Poriya
    Eazi, Seyedmohammad
    Mehrizi, Mohammad Ali Abouei
    Ahmadpour, Sajjad
    NEUROSURGICAL REVIEW, 2024, 47 (01)
  • [7] Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review
    An, Rui
    Zhao, Feng
    Wang, Liqian
    Shan, Jikang
    Wang, Xianjun
    BMJ OPEN, 2021, 11 (12):
  • [8] Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
    Leitao Sun
    Leyin Zhang
    Jieru Yu
    Yinan Zhang
    Xi Pang
    Chenghao Ma
    Minhe Shen
    Shanming Ruan
    Harpreet S. Wasan
    Shengliang Qiu
    Scientific Reports, 10
  • [9] Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
    Sun, Leitao
    Zhang, Leyin
    Yu, Jieru
    Zhang, Yinan
    Pang, Xi
    Ma, Chenghao
    Shen, Minhe
    Ruan, Shanming
    Wasan, Harpreet S.
    Qiu, Shengliang
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
    Yoon, Seung Bae
    Woo, Sang Myung
    Chun, Jung Won
    Kim, Dong Uk
    Kim, Jaihwan
    Park, Joo Kyung
    So, Hoonsub
    Chung, Moon Jae
    Cho, In Rae
    Heo, Jun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345